MedTrace Logo

Taxotere + Cisplatin in Nasopharyngeal Carcinoma

NCT00436293 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2010-11-17

No results posted yet for this study

Summary

Primary objective:

To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.

Secondary objective:

To assess tumor control and survival

Conditions

  • Nasopharyngeal Neoplasms

Interventions

DRUG

Docetaxel

75 mg/m²

DRUG

Cisplatin

75 mg/m²

Sponsors & Collaborators

Principal Investigators

  • Iris Chan · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436293 on ClinicalTrials.gov